AbbVie announced that the Food and Drug Administration (FDA) has approved the use of Humira (adalimumab) for moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) to reducing signs and symptoms in patients aged ≥2 years.

In 2008, Humira was initially approved for pJIA in patients aged ≥4 years. Humira is also indicated to reduce the signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adults; psoriatic arthritis in adults; ankylosing spondylitis in adults; moderate to severe Crohn’s disease in children and adults; moderate to severe ulcerative colitis in adults; and for the treatment of moderate to severe chronic plaque psoriasis in adults.

RELATED: Humira Gains Pediatric Crohn’s Disease Indication

Humira is available in a 10mg, 20mg, 40mg prefilled syringe, and a 40mg auto-injector pen.

For more information call (800) 633-9110 or visit